Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center

Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

August 19th 2024

A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.

Practice Patterns and Real Use of Epcoritamab and Glofitamab

August 19th 2024

A panel of experts discuss the role of odronextamab.

Bispecific therapy – management of long-term adverse events in the community setting

August 12th 2024

Bispecific therapy – treatment setting and management of short-term adverse events

August 12th 2024

Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

August 5th 2024

Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

August 5th 2024

Management of CRS and ICANS with CAR T-cell Therapy

July 29th 2024

A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.

Risk of Secondary Malignancies in Heavily Pre-Treated Population

July 29th 2024

A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.

Current Approach to Bridging Therapy in R/R DLBCL

July 29th 2024

A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART

Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

July 29th 2024

A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.

Panel Discuses Use of CD19 Bispecifics in Sequencing

July 15th 2024

Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.

Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

July 15th 2024

Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.

Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

July 15th 2024

Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.

Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

July 15th 2024

An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.

Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

June 25th 2024

Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.

Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

June 25th 2024

Medical experts highlight second-line options for treating patients with DLBCL.

Relapsed/Refractory Follicular Lymphoma: Future Directions in Care

September 22nd 2023

Key opinion leaders Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the evolving treatment landscape of follicular lymphoma and look toward future evolutions in the field.

Patient Scenario 2: A 53-Year-Old Man With Relapsed/Refractory FL

September 22nd 2023

Centering discussion on a second patient scenario of follicular lymphoma, key opinion leaders consider best therapy for patients with early or aggressive relapse.

Relapsed/Refractory Follicular Lymphoma: EZH2- and PIK3-Targeted Therapies

September 15th 2023

A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.

Relapsed/Refractory Follicular Lymphoma Treatment Armamentarium

September 15th 2023

Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting.